background: Mutations in breast cancer BRCA1/2 genes increase breast and ovarian cancer risk and are transmitted with an autosomal dominant pattern. Opinion about reproductive decisions among individuals undergoing BRCA1/2 testing in our institutions is unknown. materials and methods: Individuals (n ¼ 77) undergoing BRCA1/2 testing were included in a prospective multicentre study to assess the clinical impact of genetic testing. Demographic and clinical information, psychological status and opinion about reproductive decisions were collected in two questionnaires administered prior to testing. Opinion regarding the use of assisted reproduction techniques for hereditary cancer susceptibility among health care professionals was also collected.
Introduction
Breast cancer is one of the most common neoplasms in women and between 2 and 5% are due to high-risk penetrance genes, such as BRCA1 and BRCA2. Carriers of mutations in these genes are estimated to have a lifetime risk of 65-80% of developing breast cancer and up to 20 -45% of developing ovarian cancer (Antoniou et al., 2003; Chen and Parmigiani, 2007; Milne et al., 2008) . Breast cancer in BRCA1/2 carriers may develop at a younger age than in the average population and women may also have a higher risk of bilateral disease or multiple neoplasms (Metcalfe et al., 2004) . Male BRCA2 mutation carriers also face a higher lifetime risk of breast and prostate cancer (Levy-Lahad and Friedman, 2007) . Genetic testing is clinically available for those individuals with a personal or family history suggestive of a hereditary For Permissions, please email: journals.permissions@oxfordjournals.org predisposition. Identification of mutation carriers may impact upon their medical management, with more intensive screening recommendations starting at younger ages and the option of risk-reducing surgeries, such as prophylactic bilateral salpingoophorectomy or mastectomy (Domchek and Rebbeck, 2007; Robson and Offit, 2007) . Although screening may help to diagnose cancer at an earlier stage, it will not prevent it. In addition, prophylactic surgery may offer an incomplete risk reduction of developing cancer at follow-up (Rebbeck et al., 2004; Kauff et al., 2008) . Therefore, screening is not a 100% preventive option. Finally, the diagnosis of a genetic susceptibility to breast and/or ovarian cancer may lead to an increase in anxiety and psychological disturbance (Van Oostrom et al., 2003) .
Classically, genetic counselling of individuals undergoing BRCA1/2 testing has focused on the clinical management of mutation carriers. Some studies have addressed the impact of BRCA testing on surgical decisions for breast cancer (Schwartz et al., 2004) , the impact on adherence to screening recommendations (Foster et al., 2007) or the emotional distress associated with a positive genetic test result (Meiser, 2005) . Nevertheless, the probability of transmitting a deleterious mutation to each offspring is 50% and it has been shown that one of the main reasons for undergoing genetic testing of BRCA1/2 reported by individuals is to know if their children are at risk (Pasacreta, 2003; Meiser et al., 2006) . Therefore, it seems plausible that mutation carriers may consider remaining childless, adopting or using assisted reproduction techniques (ART), such as preimplantation genetic diagnosis (PGD) or prenatal diagnosis (PND), to prevent their offspring from inheriting a mutation.
The aim of our study was to investigate the potential implications of BRCA1/2 testing on reproductive decision making in individuals at risk and their opinion about the ethics of using ART for BRCA1/2 mutation carriers. We also aimed to investigate opinion regarding the use of PND and PGD among health care professionals.
Materials and Methods

Study population
A collaboration was established among four clinics assessing high-risk individuals to analyse the clinical and psychosocial impact of genetic testing in hereditary cancer syndromes (IMASS project). Participating centres were Hospital Vall d'Hebron, Barcelona; Institut Català d'Oncologia, Girona; Hospital Sant Joan de Reus, Tarragona and Hospital Sant Pau, Barcelona.
All individuals attending one of the four high-risk clinics and candidates for BRCA1/2 genetic testing were invited to participate in the study. A total of 89 individuals were approached between April and December 2006. All individuals were told that participation in the study involved completion of a series of questionnaires regarding the genetic testing process that would not impact their medical management. All individuals were eligible, regardless of whether they accepted or declined genetic testing. Individuals were required to be older than 18 years and needed to understand oral and written Spanish. The study was accepted by the local ethical committees and all individuals signed an informed consent prior to enrollment.
Separately, health care professionals attending a hereditary cancer symposium were asked to complete a self-reported questionnaire about their opinion on PND and PGD for BRCA1/2 mutation carriers. This study population included 90 individuals with a median age of 35 years (20-56): 68% were women, 51% did not have children, 38% were physicians, 23% were nurses and the rest were biologists (Table I) .
Questionnaires
Data were collected from self-administered questionnaires. The baseline questionnaire included demographic information such as age, gender, marital status, level of education, household income, religion and basic health information. The questionnaire was administered after the first risk-assessment visit. A second genetic evaluation questionnaire was administered prior to genetic testing. This questionnaire included specific questions related to perceived risk of cancer, source of information about the hereditary cancer syndrome, motivations and concerns towards genetic testing, psychological status measured with the HADS scale (Zigmond and Snaith, 1983; Quintana et al., 2003) and quality of life measured with the SF-12 scale (Ware et al., 1996) . Cancer diagnoses and data regarding cancer surveillance practices were confirmed by medical records or pathology reports.
The section about opinion on childbearing decisions was preceded by some general information describing the process of PND and PGD (Table II) . These definitions did not include the percentage of success, failure rate or pregnancy loss of these procedures, indications for PND or PGD, time commitment, number of visits required or the potential costs of these techniques. Individuals were asked about their opinion on different childbearing decisions if they were to receive a positive genetic test result. Secondly, individuals were asked about their opinion on the ethics of performing PND or PGD in BRCA1/2 mutation carriers (Table III) . Answers were ranked in a five-point Likert scale from 'totally agree' to 'totally disagree'. The questionnaire completed by health care professionals about their opinion on PND and PGD is summarized in Table IV .
Descriptive statistics were used to summarize the study population. Associations between individuals' characteristics and opinion about reproductive decisions and ethics of PND and PGD were evaluated using the Fisher's exact test. A logistic regression analysis was performed to assess the independent predictors associated with the opinion about reproductive decisions. All statistical analyses were performed with the statistical package for the social sciences V12 (Chicago, IL, USA). A P-value less than 0.05 was considered statistically significant.
Results
Eighty-nine individuals were eligible for the study and 12 (13%) were excluded for not answering the questions related to reproductive decisions. Demographics of the study population are summarized in Table I . Mean age of participants was 42 + 13.9 year (range 19 -88 years): 70% of the individuals had been diagnosed with cancer prior to participating in the study, 62% had children, 70% were married and 57% had a secondary/tertiary education. Regarding religion, 42% considered themselves as religious, although all subjects answered that religion did not influence their daily decision making. The 12 non-responder individuals had similar demographic characteristics for the study population (data not shown).
Twenty-eight individuals (36%) thought that they would decide to have children independently of the genetic test result and 12% thought that they would decide not to have children in case of carrying a mutation in the BRCA1/2 genes (Table V) . Forty-two individuals (55%) reported that they would consider PND in case of receiving a positive genetic result and 37 (48%) thought that they would consider PGD. Finally, 30% of the individuals thought that they would consider adopting children in the event of identifying a mutation.
A higher percentage of individuals older than 40 years thought that they would consider PND (68%) and PGD (63%) if they were found to be a mutation carrier compared with individuals younger than 40 years (P ¼ 0.02 and 0.05, respectively). The diagnosis of cancer was positively associated with reporting that they would consider PGD in the event of receiving a positive genetic result (P ¼ 0.02) (Table VI) . When controlling for gender and cancer status, older age was the only variable significantly associated with considering PND (odds ratio ¼ 3.13, P ¼ 0.03). The following questions deal with decisions related to having children that could arise in families in whom a genetic predisposition to a disease exists. Some reproductive technologies to diagnose genetic diseases or a predisposition before a child is born are available. At the moment, these types of procedures are not offered routinely in our national health system, but only under some special circumstances. If you do not feel comfortable answering these questions, please skip to the following section.
Prenatal diagnosis can be carried out when a woman is pregnant and can be used to diagnose a series of genetic diseases, including identified mutations in the family. The diagnosis is made through an amniocentesis or corion biopsy between weeks 10 and 18 approximately. Decision on interrupting the pregnancy may be made after receiving the result of the prenatal diagnosis.
Preimplantation genetic diagnosis can be performed through a process of in vitro fertilization. This is a reproductive technology in which the ovum and spermatozoa join for fertilization in the laboratory and creation of embryos and are later implanted in the woman. Before the implantation, one of the cells can be analysed to determine if the embryo is carrying the known mutation in the family. The non-carrying embryos of the mutation would be implanted.
Information provided for self-administered questionnaires for patients. Regarding the ethical questions related to the use of ART, 74 and 61% of the individuals considered that it was ethical to offer PND and PGD, respectively, for BRCA1/2 mutation carriers. Women were more likely than men to consider ethical offering PND (81 versus 56%) and PGD (69 versus 33%) (Table VII) . Also, individuals with higher educational level reported more frequently that it was ethical to offer PND (86 versus 65%, P ¼ 0.04). Finally, 74% of individuals affected by cancer thought it was ethical to offer PGD compared with 44% of healthy subjects (P ¼ 0.02).
Fifty-eight percent of health care professionals were in favour of offering PND in hereditary cancer syndromes, while 61% of them were in favour of PGD for selection of non-mutation embryo carriers with a hereditary predisposition to cancer (Table VIII) . Ninety-two percent were in favour of patients receiving adequate information about the different options for not transmitting a genetic predisposition to cancer to their offspring in the setting of high-risk cancer clinics. In fact, 89% of the health care professionals thought that the high-risk cancer clinics had the duty to inform about the different reproductive options for not transmitting a genetic predisposition to cancer to the offspring (Table VIII) .
Discussion
Our study suggests for the first time in our country that genetic testing of BRCA1/2 may influence the individual's reproduction decision making. In fact, before undergoing genetic testing, more than 10% of individuals reported that they would consider being childless in case of receiving a positive genetic test result. Moreover, half of the individuals expressed their belief that they would consider PND or PGD if they were to receive a positive genetic test result. In addition, having been diagnosed with cancer was the variable most associated with considering the potential option of PGD and to believing that PGD for BRCA1/2 non-carriers selection was ethical. Most health care professionals surveyed about reproduction options for BRCA1/2 carriers, including physicians (mainly oncologists), nurses, geneticists and biologists, also reported being in favour of offering PND and PGD to individuals with a high-penetrance genetic susceptibility to cancer. In addition, most health care professionals believed that individuals at risk of an adult-onset hereditary cancer syndrome should receive information at high risk and cancer prevention units about all of the available ART options, to avoid transmitting the mutant gene to their offspring.
In our clinical experience, we are increasingly attending individuals of childbearing age who request information about reproductive options after identification of a genetic susceptibility to cancer. Consequently, it was important that we analysed how genetic testing may influence family planning and what current options we may offer them. There was previous evidence that genetic testing for BRCA1/2 may have implications for fertility intentions in mutation carriers. In a US population, female BRCA1 carriers and women who did not know their BRCA genetic status expressed less intention of having children compared with non-carrier females, while these differences were not observed among men (Smith et al., 2004) . This finding is consistent with the observation that knowing if children are at risk is one of the most important motivations reported by individuals undergoing genetic testing (Pasacreta, 2003; Meiser et al., 2006) .
In fact, 46% of our study population considered this motivation as the most important reason for seeking BRCA1/2 testing (D. Fortuny, personal communication). It has also been reported that BRCA1/2 mutation carriers, regardless of their cancer status, may feel guilty about passing the mutation to their children (Lynch et al., 2006) . Any of these reasons could explain that in our study some BRCA1/2 carriers reported that they may prefer staying childless rather than potentially having a child with a genetic susceptibility to breast and ovarian cancer. Interestingly, adopting children was viewed as another option for one-third of the participants, while, surprisingly, around half viewed PND or PGD as valuable options for not transmitting the condition to their children. Nowadays, in our country, adoption is a widely accepted option for many couples who cope with some type of infertility or even for those who decide to have children when older. Consequently, we were not surprised with the high rate of individuals who viewed adoption as an option in case of a positive genetic result.
In the UK, where the use of PGD has recently been approved for BRCA1/2 carriers by the human fertilization and embryology authority, it was observed that 75% of mutation carriers felt that it was acceptable to offer PGD to affected individuals, although only 14% would choose this technique for themselves (Menon et al., 2007) . In another study from the USA, conducted among women at high risk of hereditary breast and ovarian cancer, 57% of the women reported that PGD was an acceptable option for high-risk individuals and 74% believed that high-risk individuals should be given information about Numbers may add over the total because individuals answered multiple options.
Reproductive decisions at breast cancer testing PGD (Quinn et al., 2008) . The percentage of individuals viewing PGD as an option in our cohort was in accordance to the previous published studies. In our study, we interpret this high acceptance as a result of asking the individuals about their opinion instead of their intention, which would result in an increased rate of acceptance of ART. Actually, the fact that older age, even after controlling for cancer status and gender, was still associated with a high acceptance of PND suggests that it is not an intention-driven result, but an opinion. In our empirical and limited experience, some couples who started the process of PGD for other high-penetrance cancer syndromes have abandoned at the time of coping with the difficulties of such process, such as the technical difficulties associated with DNA testing of the embryo, the medical implications derived from the fertility treatment in the woman or the relatively low rates of a successful pregnancy. Therefore, we think that the intention rate would likely be much lower when specifically asking individuals of reproductive age and after a thorough explanation of the whole process. According to our national law, PGD is legal 'for the detection of serious hereditary diseases, with early onset, and not subject to postnatal curative treatment according to current scientific knowledge in order to select the pre-embryos not affected; and for the detection of other alterations that could compromise the viability of the pre-embryo. The application of PGD in these cases must be communicated to the relevant health authority, which should inform the National Commission of Human Assisted Reproduction (CNRHA). The implementation of PGD for any other purpose will require the express authorization and case verification by the relevant health authority, following a favourable report from the CNRHA, which must assess the clinical, therapeutic and social aspects of each case' (BOE, 2006) . Therefore, we should interpret that PGD for selection of non-BRCA1/2 embryos would require an individualized case-by-case analysis and it might not be a straightforward process. In fact, very recently, the first two cases pending authorization by the CNRHA to undergo PGD for BRCA mutations in private Spanish fertility clinics were reported to the public media (Ricart, 2008) and a final decision is still pending.
On the other hand, application of PND for hereditary breast and ovarian cancer has not been reported (Offit et al., 2006) and we were surprised by the high percentage of individuals reporting that they would consider this option in case of a positive result. Again, we think this is a result of asking for an opinion rather than an intention. In fact, PGD for BRCA mutations may appear as a more attractive alternative to PND because it helps to ensure the establishment of a mutation-free pregnancy from the outset. In Belgium, a protocol for PGD in two couples with two different BRCA1 mutations was performed and showed that it was technically feasible to identify carrier and non-carrier embryos. In one of the couples a non-carrier embryo was transferred, but it did not lead to a successful pregnancy, while the other couple had a concomitant subfertility (Spits et al., 2007) .
Health care professionals, especially oncologists and those working in the genetic diagnosis of cancer predisposition syndromes, are commonly asked about strategies to decrease and prevent the impact of these syndromes on the families in their care. It is therefore important that we are aware of the current ART options and also to investigate the health care professional's opinion in this field. With this aim, we surveyed professionals attending a hereditary cancer symposium about their opinion on reproductive options for individuals at risk of hereditary cancer syndromes. The survey showed that more than half of them would be in favour of offering PND and PGD to individuals with a high-penetrance susceptibility to cancer. In addition, most of them (92%) thought that familial cancer units should inform individuals at risk about all available reproductive options for BRCA carriers. Consequently, the medical community seems to be in favour of providing thorough information on ART to individuals at genetic risk of cancer to help them make appropriate decisions. A limitation of our study is that it gathered views on childbearing options for BRCA carriers in individuals at risk surveyed before undergoing genetic testing and independent of being at childbearing age or not. Therefore, it may not really reflect their fertility attitudes or intentions. However, it is the first study performed in our country analysing the opinion of individuals undergoing BRCA1/2 genetic testing on reproductive decision making and it provides ground upon which future and more specific studies can be based. Finally, information on PND and PGD was provided by way of a brief explanation in a box before the questions and we cannot guarantee the degree of understanding of these techniques among individuals. In fact, details of the procedures and rates of failures were not reported in the explanation and this may have falsely inflated the proportion of individuals reporting that they would consider one of these options. Nevertheless, the scope of this study was to obtain the opinion, and not the intentions, on fertility decision making and a study of attitudes would require a more complex design. Finally, we did not ask about all potential options for reproduction in case of a positive genetic test result, such as the use of donor gametes, and therefore we cannot provide an overall percentage of acceptance.
In conclusion, results from our study suggest that BRCA1/2 genetic testing may impact on the reproductive decision making of individuals undergoing mutation analysis. Therefore, potential consequences of BRCA1/2 testing on fertility should be fully incorporated and discussed in the genetic counselling process and health care professionals working in this field should inform their patients about available options for not transmitting a genetic susceptibility to cancer. Reproductive decisions at breast cancer testing
